Menarini is the world’s largest Italian biopharmaceutical company, focused on delivering differentiated ethical and consumer healthcare brands across the region. With over 3,000 professionals in 13 major markets, Menarini Asia-Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management and offers an unparalleled customer experience to partners wanting to tap into the Asia-Pacific growth story.READ MORE
About Menarini Group
Menarini is the largest Italian multinational biopharmaceutical company with nearly 16,000 employees worldwide and presence in more than 100 countries, including Europe, Africa, Middle East, Asia-Pacific, Central and Latin America.
Founded in 1886, Menarini markets products in key therapeutic fields including respiratory, cardiovascular, gastroenterology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics.
Menarini launched into Men’s Health with the first and only drug specifically developed to treat Premature Ejaculation (“PE”), now approved in over 60 countries. In Asia-Pacific, the drug has been launched in Australia, China, Hong Kong, Korea, Malaysia, Singapore, and Taiwan. PE affects nearly 1 in 3 men in Asia-Pacific but is often under detected and under treated. Based on robust clinical trials involving over 16,000 men worldwide, Menarini’s Rx treatment for PE is proven to be well-tolerated and to significantly improve control over ejaculation and sexual satisfaction for the couple.
World’s Most Patient Friendly Companies
Menarini: Top Ten Most “Patient Friendly” Companies
An independent Corporate Reputation Survey of Pharma Companies, including 800 patient groups in 43 countries worldwide, ranked Menarini amongst the world’s top ten Pharmaceutical companies closest to patients’ needs.
Please refer to the News Corner for the full information about the survey.